
Akkermansia
Small trials, mostly of pasteurized Akkermansia and mostly run by researchers linked to the companies that sell it, suggest modest improvements in insulin sensitivity and less weight regain after dieting. The largest trial missed its main goal, and benefits appear mainly in people with little Akkermansia to begin with.
Quick decision guide
May help most
Adults with overweight, prediabetes or metabolic syndrome who want to try an option with early evidence, alongside diet and medical care
Common dosing range
Studied doses of pasteurized Akkermansia: 10 billion cells per day for 3 months and 30 billion cells per day for 4 months; the dose in the 24-week weight-maintenance trial is not stated in its abstract
When to expect effects
3 to 6 months in trials
Watch out for
Live and pasteurized products are different; most evidence is for pasteurized; safety in pregnancy, breastfeeding and young children has not been established
What is it
Akkermansia muciniphila is a bacterium that normally lives in the mucus layer lining the human gut. It is sold as a supplement in two quite different forms. Pasteurized Akkermansia is heat-treated so the cells are no longer alive; the European Food Safety Authority's safety review of it required that viable cells be below the limit of detection (fewer than 10 per gram). Live Akkermansia contains living bacteria and is sold either on its own or in multi-strain products with other bacteria and fiber. The trials below used one form or the other, and a result for one form does not automatically apply to the other. In the EU, the European Food Safety Authority (EFSA) judged pasteurized Akkermansia safe as a novel food at up to 34 billion cells a day for adults, excluding pregnant and breastfeeding women (2021), and in 2025 for teenagers aged 12 to 17 at up to 21 billion cells a day (ages 12 to 13) or 30 billion (ages 14 to 17). The FDA's GRAS Notice Inventory (last updated 2026-11-02, checked 2026-11-19) lists no GRAS notice for Akkermansia.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
insulin sensitivity Limited Evidence | About 29 percent better insulin sensitivity in a 32-person pilot; no difference in the main measure of a 142-person trial | Adults with prediabetes or insulin resistance and low gut Akkermansia | 3 to 4 months |
weight regain after dieting Limited Evidence | About 2 kg less weight regain over 24 weeks than placebo | Adults who have just lost weight on a diet | 24 weeks |
blood sugar in type 2 diabetes (live multi-strain product) Limited Evidence | HbA1c 0.6 points lower than placebo; borderline effect on after-meal glucose | Adults with type 2 diabetes on usual care | 12 weeks |
weight and HbA1c in type 2 diabetes (live single strain) Limited Evidence | No difference from placebo overall | Possibly people with low gut Akkermansia (subgroup finding) | 12 weeks |
muscle strength in older adults Limited Evidence | Statistically significant gain in leg extensor peak torque versus placebo | Adults aged 60 and over | 12 weeks |
insulin sensitivity
- Effect
- About 29 percent better insulin sensitivity in a 32-person pilot; no difference in the main measure of a 142-person trial
- Best fit
- Adults with prediabetes or insulin resistance and low gut Akkermansia
- Time
- 3 to 4 months
weight regain after dieting
- Effect
- About 2 kg less weight regain over 24 weeks than placebo
- Best fit
- Adults who have just lost weight on a diet
- Time
- 24 weeks
blood sugar in type 2 diabetes (live multi-strain product)
- Effect
- HbA1c 0.6 points lower than placebo; borderline effect on after-meal glucose
- Best fit
- Adults with type 2 diabetes on usual care
- Time
- 12 weeks
weight and HbA1c in type 2 diabetes (live single strain)
- Effect
- No difference from placebo overall
- Best fit
- Possibly people with low gut Akkermansia (subgroup finding)
- Time
- 12 weeks
muscle strength in older adults
- Effect
- Statistically significant gain in leg extensor peak torque versus placebo
- Best fit
- Adults aged 60 and over
- Time
- 12 weeks
Evidence for 5 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
insulin sensitivity
Biomarker supportIn a 3-month pilot trial in 32 overweight or obese adults with insulin resistance who completed it (40 enrolled), 10 billion Akkermansia cells a day, either live or pasteurized, were safe and well tolerated. Compared with placebo, the pasteurized form improved insulin sensitivity by about 29 percent, lowered blood insulin by about 34 percent and total cholesterol by about 9 percent; the abstract reports these gains for the pasteurized form. A larger 4-month trial in 142 adults with metabolic syndrome in Ireland and Germany gave 30 billion pasteurized cells a day and did not improve its main measure, whole-body insulin sensitivity, compared with placebo. Improvements appeared only in exploratory subgroups, mainly people with low Akkermansia levels at the start. Authors of both trials hold patents on Akkermansia or co-founded or work for A-Mansia Biotech or The Akkermansia Company, which develop the pasteurized product.
Bottom line: Promising in a small pilot, not confirmed by the larger trial's main result.
Evidence is mixed
The 142-person trial found no difference from placebo in its primary insulin sensitivity measure; benefits were seen only in exploratory subgroups.
weight regain after dieting
Supplement benefitIn a 2026 trial, 90 adults with overweight or obesity first lost at least 8 percent of their weight on an 8-week low-calorie diet, then took pasteurized Akkermansia (strain MucT) or placebo for 24 weeks on a healthy diet. Weight regain was 1.2 kg with Akkermansia and 3.2 kg with placebo. How much Akkermansia people had at the start was linked with how their heart and metabolic markers responded, and no serious treatment-related side effects were seen. The company's co-founder and other company staff were among the authors and inventors on a related patent. This is one trial and needs confirming.
Bottom line: One trial found modestly less weight regain after a diet.
blood sugar in type 2 diabetes (live multi-strain product)
Biomarker supportA 12-week trial in 76 adults with type 2 diabetes tested a live multi-strain product (WBF-011) containing Akkermansia muciniphila with four other bacteria and inulin fiber, taken twice a day. Compared with placebo, it lowered total blood sugar over 180 minutes after a standard test meal (glucose area under the curve, minus 36.1 mg/dL per 180 minutes), just reaching statistical significance, and lowered HbA1c by 0.6 points, a secondary outcome. Because the product contained several bacteria and fiber, the effect cannot be credited to Akkermansia alone. All authors were employees and shareholders of the company that makes the product.
Bottom line: A small company trial of a mixed product; not a replacement for diabetes treatment.
weight and HbA1c in type 2 diabetes (live single strain)
No benefit foundIn a 12-week Chinese trial in 58 adults with overweight or obesity and type 2 diabetes, a live Akkermansia strain (AKK-WST01, given as live bacteria according to the trial registry) plus lifestyle advice did not lower body weight or HbA1c more than placebo plus the same advice; both groups improved. People with low Akkermansia at the start were colonized well and lost weight, fat and HbA1c, while people with high starting levels were poorly colonized and did not improve. The authors declared no competing interests.
Bottom line: Overall, no better than placebo; any benefit may be limited to people low in Akkermansia.
muscle strength in older adults
Supplement benefitIn a 12-week Korean trial in 100 adults aged 60 and over, a pasteurized Akkermansia strain from a different company (HB05, 10 billion cells a day) improved peak strength of the left leg extensor muscles more than placebo and raised follistatin, a protein that counteracts the muscle-limiting protein myostatin. No safety concerns were reported. Some authors were employees of the company that makes the strain. Hand grip strength did not change. This is one trial with a laboratory strength measure.
Bottom line: One small trial; strength training remains the proven approach.
How it works
How to take it
What to track
Bottom line: Choose the form that was actually studied (most data are for pasteurized), at a studied dose, and judge it after about 3 months.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Long-term safety beyond 6 months is unknown; the trials were small and short
Who should avoid it
- Pregnant or breastfeeding women: EFSA concluded in 2025 that safety of pasteurized Akkermansia in pregnancy and breastfeeding has not been establishedSourceTurck et al., 2025 · PMC
- Children under 12: EFSA's safety assessments cover adults and teenagers from age 12 only
Pregnancy & breastfeeding
Not established. EFSA's 2021 safety review covered adults excluding pregnant and breastfeeding women, and its 2025 review found no evidence provided for safety in pregnancy and breastfeeding. Talk with your doctor before using any Akkermansia product while pregnant or breastfeeding.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Should I choose live or pasteurized Akkermansia?⌄
Most of the published trials, including the weight-regain and metabolic syndrome trials, used pasteurized Akkermansia. In the 2019 pilot trial, the metabolic improvements reported in the abstract were for the pasteurized form. Live forms have been tested in fewer trials, one of them as part of a multi-strain mix. Check that the form and strain on the label match a trial.
Will Akkermansia help me lose weight?⌄
Not by much on its own. In one trial, people who had just lost weight on a diet regained about 2 kg less over 24 weeks with pasteurized Akkermansia than with placebo. In people with type 2 diabetes, a live strain did not reduce weight more than placebo overall.
Is Akkermansia approved?⌄
In the EU, the food safety agency EFSA judged pasteurized Akkermansia safe as a novel food at up to 34 billion cells a day for adults (2021), and in 2025 for teenagers from 12 at lower amounts (up to 21 billion cells a day at ages 12 to 13 and 30 billion at ages 14 to 17). The FDA's GRAS Notice Inventory (last updated 2026-11-02) lists no GRAS notice for Akkermansia. In the US, supplements do not need FDA approval before they are sold.
Can I take Akkermansia with my medicines or other supplements?⌄
No interaction studies have been published. Trials in people with type 2 diabetes did not report interaction problems, but none was designed to study interactions. Ask your doctor or pharmacist to check your own list, especially if you take diabetes medicines, since a change in blood sugar would matter.
Why did it work for some people and not others?⌄
Several trials found that people with little Akkermansia in their gut at the start improved, while people with plenty did not. Your starting level can only be measured with a stool test.
References by claim
weight regain after dieting
Mount et al., 2026 · PubMed (2026) link
blood sugar in type 2 diabetes (live multi-strain product)
Perraudeau et al., 2020 · PMC (2020) link
weight and HbA1c in type 2 diabetes (live single strain)
Zhang et al., 2025 · PubMed (2025) link
muscle strength in older adults
Kang et al., 2024 · PMC (2024) link
Track Akkermansia with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: These statements have not been evaluated by the FDA. This page is educational, not a substitute for personalized medical advice. Evidence grades are AI-assisted assessments. Talk to your doctor before starting any new supplement, especially if you’re pregnant, breastfeeding, on medications, or managing a chronic condition.
